Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom

Biogen has bounced back on the market over the past year, and that kind of recovery puts fresh focus on a simple question for you as a shareholder or potential buyer: Is the current share price aligned with what the business may realistically produce in cash over time, based on its existing drugs and pipeline investments? Over the past 12 months Biogen has delivered a 58.6% share price gain, which raises the stakes on whether the recent momentum is fully grounded in its future cash...